US2005164235A1PendingUtilityA1
Modified iRNA agents
Priority: Apr 17, 2003Filed: Sep 21, 2004Published: Jul 28, 2005
Est. expiryApr 17, 2023(expired)· nominal 20-yr term from priority
C12N 2320/51C12N 15/111A61P 35/02C12N 2310/323A61K 47/554A61P 31/14A61P 35/00C12N 2310/14C12N 2310/344C12N 2310/3515C12N 2310/11C07H 21/02C12N 15/113C12N 2310/321C12N 2330/30A61K 47/55C12N 2320/32C12N 2310/315
68
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a carbohydrate; or a steroid, e.g., cholesterol, which is optionally substituted with at least one carbohydrate. is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.
Claims
exact text as granted — not AI-modified1 . An iRNA agent comprising a first strand and a second strand, wherein at 2 least one subunit having a formula (I) is incorporated into at least one of said strands:
wherein:
X is N(CO)R 7 , NR 7 or CH 2 ;
Y is NR 8 , O, S, CR 9 R 10 , or absent;
Z is CR 11 R 12 or absent;
Each of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is, independently, H, OR a , OR b , (CH 2 ) n OR a , or (CH 2 ) n OR b , provided that at least one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is OR a or OR b and that at least one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is (CH 2 ) n OR a , or (CH 2 ) n OR b ;
Each of R 5 , R 6 , R 11 , and R 12 is, independently, H, C 1 -C 6 alkyl optionally substituted with 1-3 R 13 , or C(O)NHR 7 ; or R 5 and R 11 together are C 3 -C 8 cycloalkyl optionally substituted with R 14 ;
R 7 is Rd; or C 1 -C 20 alkyl substituted with NR c R d or NHC(O)R d ;
R 8 is C 1 -C 6 alkyl;
R 13 is hydroxy, C 1 -C 4 alkoxy, or halo;
R 14 is NR c R 7 ;
R a is:
R b is
Each of A and C is, independently, O or S;
B is OH, O − , or
R c is H or C 1 -C 6 alkyl;
R d is a carbohydrate radical; or a steroid radical, which is optionally tethered to at least one carbohydrate radical; and
n is 1-4.
2 . The compound of claim 1 , wherein X is N(CO)R 7 or NR 7 , Y is CR 9 R 10 , and Z is absent.
3 . The compound of claim 2 , wherein R 1 is (CH 2 ) n OR b and R 3 is OR a .
4 . The compound of claim 3 , wherein R 1 and R 3 are cis.
5 . The compound of claim 3 , wherein R 1 and R 3 are trans.
6 . The compound of claim 3 , wherein n is 1.
7 . The compound of claims 3 , A is 0.
8 . The compound of claim 3 , wherein A is S.
9 . The compound of claim 2 , wherein R 1 is (CH 2 ) n OR b and R 3 is OR b .
10 . The compound of claim 2 , wherein R 1 is (CH 2 ) n OR a and R 3 is OR b .
11 . The compound of claim 3 , wherein R 7 is (CH 2 ) 5 NHR d or (CH 2 ) 5 NHC(O)R d .
12 . The compound of claim 3 , wherein Rd is chosen from the group of a galactose radical, an N-acetylgalactose radical, or a mannose radical.
13 . The compound of claim 2 , wherein R 1 is OR b and R 3 is (CH 2 ) n OR b .
14 . The compound of claim 2 , wherein R 1 is OR b and R 3 is (CH 2 ) n OR b .
15 . The compound of claim 2 , wherein R 1 is OR a and R 3 is (CH 2 )OR b .
16 . The compound of claim 15 , wherein R 1 and R 3 are cis.
17 . The compound of claim 15 , wherein R 1 and R 3 are trans.
18 . The compound of claim 15 , wherein n is 1.
19 . The compound of claim 2 , wherein R 1 is (CH 2 ) n OR b and R 9 is OR a .
20 . The compound of claim 19 , wherein R 1 and R 9 are cis.
21 . The compound of claim 19 , wherein R 1 and R 9 are trans.
22 . The compound of claim 19 , wherein n is 1.
23 . The compound of claim 2 , wherein R 1 is OR a and R 9 is (CH 2 ) n OR b .
24 . The compound of claim 23 , wherein R 1 and R 9 are cis.
25 . The compound of claim 23 , wherein R 1 and R 9 are trans.
26 . The compound of claim 23 , wherein n is 1.
27 . The compound of claim 2 , wherein R 1 is (CH 2 ) n OR b and R 9 is OR b .
28 . The compound of claim 2 , wherein R 1 is (CH 2 ) n OR a and R 9 is OR b .
29 . The compound of claim 2 , wherein R 1 is OR b and R 9 is (CH 2 ) n OR b .
30 . The compound of claim 2 , wherein R 1 is OR b and R 9 is (CH 2 ) n OR a .
31 . The compound of claim 2 , wherein R 3 is (CH 2 ) n OR b and R 9 is OR a .
32 . The compound of claim 2 , wherein R 3 is (CH 2 ) n OR b and R 9 is OR b .
33 . The compound of claim 2 , wherein R 3 is (CH 2 ) n OR a and R 9 is OR b .
34 . The compound of claim 2 , wherein R 3 is OR a and R 9 is (CH 2 ) n OR b .
35 . The compound of claim 2 , wherein R 3 is OR b and R 9 is (CH 2 ) n OR b .
36 . The compound of claim 2 , wherein R 3 is OR b and R 9 is (CH 2 ) n OR a .
37 . The compound of claim 1 , wherein one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is OR a and one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is (CH 2 ) n OR b .
38 . The compound of claim 1 , wherein one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is (CH 2 ) n OR a and one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is OR b .
39 . The compound of claim 1 , wherein one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is OR b and one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is (CH 2 ) n OR b .
40 . An iRNA agent comprising a first strand and a second strand, wherein at least one subunit is derivatized with a moiety comprising a carbohydrate radical or a steroid radical, the steroid radical being optionally tethered to at least one carbohydrate radical, which enhances entrance into a cell.
41 . The compound of claim 40 , wherein the subunit is derivatized with a galactose radical, an N-acetylgalactose radical, or a mannose radical.
42 . The compound of claim 40 , wherein the subunit is derivatized with a steroid tethered to at least one carbohydrate radical.
43 . The iRNA agent of claim 40 , comprising at least one one subunit having a formula (I) is incorporated into at least one of said strands:
wherein:
X is N(CO)R 7 , NR 7 or CH 2 ;
Y is NR 8 , O, S, CR 9 R 10 , or absent;
Z is CR 11 R 12 or absent;
Each of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is, independently, H, OR a , OR b , (CH 2 ) n OR a , or (CH 2 ) n OR b , provided that at least one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is OR a or OR b and that at least one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is (CH 2 ) n OR a , or (CH 2 ) n OR b ;
Each of R 5 , R 6 , R 11 , and R 12 is, independently, H, C 1 -C 6 alkyl optionally substituted with 1-3 R 13 , or C(O)NHR 7 ; or R 5 and R 11 together are C 3 -C 8 cycloalkyl optionally substituted with R 14 ;
R 7 is Rd; or C 1 -C 20 alkyl substituted with NR c R d or NHC(O)Rd;
R 8 is C 1 -C 6 alkyl;
R 13 is hydroxy, C 1 -C 4 alkoxy, or halo;
R 14 is NR c R 7 ;
R a is:
R b is
Each of A and C is, independently, O or S;
B is OH, O − , or
R c is H or C 1 -C 6 alkyl;
R d is a carbohydrate radical; or a steroid radical, which is optionally tethered to at least one carbohydrate radical; and
n is 1-4.
44 . The compound of claim 43 , wherein R d is chosen from a galactose radical, an N-acetylgalactose radical, or a mannose radical.
45 . The compound of claim 42 , wherein R d is steroid tethered to at least one carbohydrate radical.
46 . The compound of claim 43 , wherein X is N(CO)R 7 or NR 7 , Y is CR 9 R 10 , and Z is absent.
47 . The compound of claim 46 , wherein R 1 is (CH 2 ) n OR b and R 3 is OR a .
48 . The iRNA agent of claim 40 , wherein the iRNA is 21 nucleotides in length and there is a duplex region of about 19 pairs.
49 . The iRNA agent of claim 40 , wherein the iRNA agent includes a duplex region between 17 and 23 pairs in length.
50 . The compound of claim 40 , wherein the first or second strand is a sense strand, and the moiety is attached to the sense strand.
51 . The compound of claim 50 , wherein the moiety is attached to a 3′ terminal subunit.
52 . The compound of claim 50 , wherein the moiety is attached to a 5′ terminal subunit.
53 . The compound of claim 50 , wherein the moiety is attached an internal subunit.
54 . The iRNA agent of claim 40 , wherein the moiety enhances entrance into a primary cell.
55 . The iRNA agent of claim 40 , wherein the moiety enhances entrance into a hepatocyte cell.
56 . The iRNA agent of claim 40 , wherein the cell comprises an exogenous gene, and the iRNA agent targets the exogenous gene.
57 . The iRNA agent of claim 56 , wherein the exogenous gene is a hepatitis viral gene.
58 . A composition comprising an iRNA agent to which a carbohydrate radical or a steroid radical, which is optionally substiuted with at least one carbohydrate radical is conjugated, which is free of, has a reduced amount of, or is essentially free of, other reagents that facilitate or enhance delivery through the cell membrane.
59 . The composition of claim 58 , wherein said composition is free of, has a reduced amount of, or is essentially free of: an additional lipophilic moiety; a transfection agent, e.g., concentrations of an ion or other substance which substantially alters cell permeability to an iRNA agent.
60 . A method of modulating expression of a target gene in a subject, the method comprising: administering an iRNA agent of claim 1 to a subject.
61 . A pharmaceutical composition comprising an iRNA agent of claim 1 and a pharmaceutically acceptable carrier.
62 . A kit comprising an iRNA agent of claim 1 , a sterile container in which the iRNA agent is disclosed, and instructions for use.
63 . A method of treating a human having or at risk for developing a disorder of the liver, the method comprising administering an iRNA agent of claim 1 or 40 .
64 . The method of claim 63 , wherein the disorder of the liver is infection with a hepatitis virus.
65 . The method of claim 64 , wherein the virus is HCV.
66 . The method of claim 64 , wherein the virus is HBV.
67 . The iRNA agent of claim 1 , wherein the iRNA agent comprises a first subunit in which R d is a carbohydrate radical, and a second subunit in which R d is a steroid radical, which is optionally tethered to at least one carbohydrate radical.
68 . The iRNA agent of claim 67 , wherein the first and second subunits are incorporated into the same strand.
69 . The iRNA agent of claim 67 , wherein the first and second subunits are incorporated into different strands.
70 . The iRNA of claim 67 , wherein R d in the first subunit is a galactose radical.
71 . The iRNA agent of claim 67 , wherein R d in the first subunit is an N-acetylgalactoseamine radical.
72 . The iRNA agent of claim 67 , wherein R d in the first subunit is mannose radical.
73 . The iRNA agent of claim 67 , wherein R d in the second subunit is a steroid radical.
74 . The iRNA agent of claim 73 , wherein R d in the second subunit is a cholesterol radical.
75 . The iRNA agent of claim 73 , wherein R d in the second subunit is a cholanic acid radical.
76 . The iRNA agent of claim 1 , wherein the iRNA agent comprises a first subunit and a second subunit in which R d is a carbohydrate radical in both the first and second subunits.
77 . The iRNA agent of claim 76 , wherein R d is the same carbohydrate radical in the first and second subunit.
78 . The iRNA agent of claim 76 , wherein the carbohydrate radical in the first subunit is different from the carbohydrate radical in the second subunit.
79 . An iRNA agent comprising a first strand and a second strand, wherein at least one subunit is derivatized with a porphyrin, which enhances entrance into a cell.
80 . The iRNA agent of claim 79 , wherein the porphyrin further comprises a carbohydrate radical; or a steroid radical optionally substituted with at least one carbohydrate radical.Join the waitlist — get patent alerts
Track US2005164235A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.